주요메뉴 바로가기 본문 바로가기

주메뉴

IBS Conferences

김진수

DirectorKIM Jin-Soo

  • KIM Jin-Soo DirectorKIM Jin-Soo

Leading the CRISPR genome editing revolution

Contact Info

Tel. +82-2-880-6643

Address

IBS Center for Genome Engineering
Room 106, Building 503, Seoul National University,
1, Gwanak-ro, Gwanak-gu, Seoul 151-747

Director
Director KIM Jin-Soo

Director KIM Jin-Soo

Professor Kim is the director of the Center for Genome Engineering, established in 2014. Throughout his independent scientific career in industry and academia, Prof. Kim has developed and improved three different types of programmable nucleases, namely, ZFNs, TALENs, and CRISPR/Cas9 systems. These tools are now widely used for genome editing in human stem cells, model organisms, livestock, and plants.

Introduction
graphic image for Research Center

Genome engineering via programmable nucleases including the CRISPR-Cas system

  • - Genome editing in plants, animals, and cultured human cells including iPS/ES cells
  • - Engineered nuclease-mediated gene and cell therapy
  • - Functional genomics using genome-scale libraries of programmable nucleases
Main research activities

We focus on developing programmable nucleases that enable genome editing in plants, animals, and cultured cells including human pluripotent stem cells. These nucleases cleave chromosomal DNA in a targeted manner, producing DNA double-strand breaks (DSBs), whose repair via endogenous mechanisms gives rise to targeted genome modification in cells and whole organisms. For the last ten years or so, we have developed three different types of programmable nucleases, namely, zinc finger nucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and RNA-guided engineered nucleases (RGENs) derived from the type II CRISPR/Cas prokaryotic adaptive immune system. These nucleases are now used widely in almost every discipline in biology, biotechnology, and molecular medicine. We have opened websites to help researchers choose unique RGEN target sites suitable for gene disruption (www.rgenome.net) and TALEN sites in 18,740 protein-coding genes and 274 miRNA sequences in the human genome (www.talenlibrary.net).

We will continue our efforts to improve and expand genome editing technologies. In addition, we plan to use these powerful tools to discover new genes associated with various disease phenotypes such as viral replication and cancer and to develop methods of gene/cell therapy for the treatment of both acquired and genetic diseases. We also focus on developing genome-engineered pigs appropriate for organ transplantation and value-added crops.

Organization

Organization

Main research results
  • Digenome-seq: Genome-wide Profiling of CRISPRCas9 Off-target Effects in Human Cells
    (Nature Method, 2015)
  • DNA-free Genome Editing in Plants with Preassembled CRISPR-Cas9 Ribonucleoproteins
    (Nature Biotechnology, 2015)
  • Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9
    (Cell Stem Cell, 2015)
  • Highly Efficient RNA-Guided Genome Editing in Human Cells via Delivery of Purified Cas9 Ribonucleoproteins
    (Genome Research, Selected as Genome Research Cover Paper, 2014)
  • A Guide to Genome Engineering with Programmable Nucleases (Nature Reviews Genetics, 2014)
Personnel
Personnel status
Total55
Gender27(Male), 28(Female)
Korean/ International51(Korean), 4(International)
Degree
Position

As of Dec. 2015

Research

Are you satisfied with the information on this page?

Content Manager
Center for Genome Engineering : Kim, Sang Tae   042-878-8304
Last Update 2017-01-12 10:14